Physician profile
Wade Baggs
NPI 1174050314
$3,416.78
in general payments reported to CMS, 2019-2025
30 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $263 · 2021: $665 · 2022: $714 · 2023: $604 · 2024: $492 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.81 | 2021-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $429.74 | 2020-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $384.20 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.78 | 2019-2025 | Ofev, Jardiance, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $276.75 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $182.28 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $181.21 | 2019-2024 | |
| Ucb, INC. | $177.10 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $174.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $146.58 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $101.30 | 2020-2022 | |
| Exact Sciences Corporation | $74.06 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $66.58 | 2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $50.42 | 2021-2024 | Livalo |
| Biohaven Pharmaceutical Holding Company LTD. | $49.47 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.37 | 2021 | |
| Scilex Pharmaceuticals INC. | $32.26 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.84 | 2021 | |
| Horizon Therapeutics Plc | $26.95 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $23.95 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.87 | 2021 | |
| Corcept Therapeutics | $18.86 | 2022 | |
| Eisai INC. | $17.54 | 2021 | |
| Fresenius Kabi USA, LLC | $17.34 | 2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $16.47 | 2023 | Strensiq |
| Dexcom, INC. | $16.45 | 2024 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $16.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.64 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $14.48 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Baggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.